The balance of activation and tolerance of the immune system in the body is very important, and when this balance is broken, various immune diseases are triggered. Because the regulation of the immune system is mediated by the cells responsible for it, this can be achieved by manipulating immune cells. Development of a cell therapy agent capable of regulating the activity and tolerance of the body's immune system can be used as a therapeutic vaccine for intractable immune disease.
Cell therapy is therapy in which living cells are injected or implanted into a patient in order to repair and replace diseased or damaged cells or tissues for the restoration of normal functions. The living cells can be isolated from tissues using cell-specific markers for ex vivo culture and can be manipulated for expansion and differentiation with chemical, physical, or biological treatments.
The Quratis inc. is currently developing dendritic cell-based cell therapy platform with a variety of indications, including cancers, autoimmune disease, and infectious diseases. Since dendritic cells play important roles in both innate immune response and adaptive immune response, modulation of dendritic cells is useful for the treatment of immune-related disorders.
The Quratis inc. is currently developing dendritic cell-based cell therapies to treat TB and cancers by activating dendritic cells to boost immune responses. We are also developing the plasmacytoid dendritic cell-based therapies to treat arthritis by suppressing adverse immune responses.